Migraine Headache
FDA issues not approvable letter for migraine treatment
Published in Medical Letter on the CDC and FDA, November 23rd, 2003
The letter was issued based on the FDA's conclusion that while MT 300 achieved its primary endpoint, it failed to achieve statistical significance versus placebo for the relief at 2 hours of the secondary symptoms of migraine (nausea, sensitivity to light, and sensitivity to sound).
No clinical safety issues were identified in the letter, nor were any non-clinical issues cited as impacting the FDA's decision to issue the not approvable letter.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Bladder Cancer
Bladder cancer detected by high-volume molecular analysis of urine sediment - HIV/AIDS Therapy
Antiretroviral therapy should begin when T cells drop below 350 cells/microL - Antimicrobials
Levofloxacin bioequivalence suffers when given with juice and cereal - Genetic Disorder
Pelizaeus-Merzbacher disease and spastic paraplegia caused by same gene - RNA Research
Novel method to replicate mRNA for gene expression analysis developed - Smallpox Vaccine
Postexposure vaccination is effective for prevention of smallpox - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
